DRUG BRIGHT MINDS BIOSCIENCES INC.

NEUTRAL Impact: 2/10 6-K
Horizon weeks Filed Jun 3, 2026 Processed 11d 23h ago SEC 0001062993-26-003005
Notable filing: 6-K
Latest settled — T+1d ⚠ clustered
DRUG ▲ +0.11% at T+1d
NEUTRAL call ✓ call won +0.11% · α vs SPY -0.29% · entry $74.42 → $74.50
Next anchor: T+5d due 5d ago
Last close $60.95 (close Jun 12) · -18.10% from $74.42 entry
Entry anchored
Jun 3, 2026
via day open
T+1d
+0.11%
call +0.11% · α -0.29%
$74.50
settled 11d ago
T+5d
call — · α —
due 5d ago
T+20d
call — · α —
in 17d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Bright Minds Biosciences filed its management information circular for the March 31, 2026 annual general meeting. The circular covers routine matters: election of six directors (including one new nominee, Dr. Steve Farr), reappointment of auditor De Visser Gray LLP, and advisory receipt of annual financial statements. No material financial data, earnings, or operational catalysts are disclosed — this is a standard proxy solicitation filing with no stock-moving content.

Actionable Insight

This is a routine AGM circular with no trading catalyst. The addition of Dr. Steve Farr to the board adds rare-disease drug development expertise but is not a near-term stock mover. Monitor the company's clinical pipeline updates and future earnings filings for material developments.

Key Facts

  • AGM scheduled for March 31, 2026 at 10:00 a.m. PT in Vancouver, BC
  • Shareholders to elect six directors: five incumbents plus new nominee Dr. Steve Farr (former Zogenix CEO)
  • Auditor De Visser Gray LLP nominated for reappointment; audit fees were $77,000 for FY2025 vs $60,500 for FY2024
  • Record date for voting: February 10, 2026; 9,787,161 common shares outstanding
  • Top holders: Janus Henderson (16.3%), Cormorant Global Healthcare (10.82%), CEO Ian McDonald (10.27%)
  • No financial results, guidance, or operational milestones reported in this filing

Financial Impact

No financial impact — routine proxy filing with no earnings or material transaction

Risk Factors

  • Clinical-stage biotech with no approved products — binary pipeline risk
  • CEO Ian McDonald holds 361,765 warrants at $1.70 expiring December 2028, representing potential dilution of ~3.7% of outstanding shares if exercised

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001062993-26-003005
Exhibit: exhibit99-2.htm0001062993-26-003005
Exhibit: exhibit99-1.htm0001062993-26-003005
Exhibit: exhibit99-4.htm0001062993-26-003005
Exhibit: exhibit99-5.htm0001062993-26-003005
Document: form6k.htm0001062993-26-003005
Document: 0001062993-26-003005-index-headers.html0001062993-26-003005
Document: 0001062993-26-003005-index.html0001062993-26-003005
Document: 0001062993-26-003005.txt0001062993-26-003005
2 reports for DRUG
Performance horizon
Filters
Rows
Reports for DRUG — sortable, filterable
Type Now
Jun 3, 2026
11d ago
6-K
NEUTRAL ★ 2/10
$74.42 $74.50▲ +0.11%▼ −0.29%$60.95 (−18.10%)
Jun 2, 2026
12d ago
6-K
NEUTRAL ★ 2/10
$76.78 $74.42▼ −3.07%▼ −2.38%$60.95 (−20.62%)
Showing 2 of 2

US Market Status

Market Closed — Opens in 4h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access